Company Number: 13630489

Analysis Date: 2025-07-29 17:28 UTC

1. Credit Opinion: DECLINE
   LANGSMEAD LTD demonstrates persistent net liabilities and negative shareholders' funds over the last three years, indicating weak financial health. The company’s inability to generate positive net assets or working capital suggests limited capacity to service debt or absorb financial shocks. Given the micro-entity classification and absence of employees, the operational scale is minimal, increasing risk. Without evidence of revenue growth or profit generation, extending credit would be imprudent.

2. Financial Strength:
   The balance sheet reveals a consistent negative net asset position: -£6,733 as of 30 September 2024, worsening slightly from prior years. Current liabilities marginally exceed current assets, resulting in negative net current assets of approximately -£1,833, which signals working capital deficiency. The company holds no fixed assets, and accrued liabilities (accruals and deferred income) further exacerbate the deficit. This weak equity base and near break-even current asset position reduce financial resilience.

3. Cash Flow Assessment:
   Liquidity appears strained due to current liabilities slightly surpassing current assets, indicating potential difficulty in meeting short-term obligations. The static level of current assets (around £310k) against current liabilities (~£312k) over multiple years suggests no material improvement in cash flow management or operational cash generation. The absence of employees and minimal operational notes raise concerns about sustainable cash inflows.

4. Monitoring Points:

• Track changes in net current assets and net asset position in subsequent filings to detect any improvement or further deterioration.
• Monitor accruals and deferred income levels as they contribute to the net liability position.
• Review any updates on operational scale or introduction of income-generating activities to assess future cash flow capacity.
• Watch for director or shareholder capital injections or restructuring that could strengthen the balance sheet.